Anthony Killarney

Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA.

BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX.

Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts.

EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA.

Blossom Biosciences Ltd. provides molecular and cell biology research services. The company is based in Hong Kong, Hong Kong. Andrew J. Phillips has been the CEO of the Chinese company since 2021.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million.

Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022.

The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA.

Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ.

Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom.

Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc.

Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors.